A Nutritional Approach for the Management of Chemotherapy-Induced Diarrhea in Patients with Colorectal Cancer
- PMID: 35565769
- PMCID: PMC9100930
- DOI: 10.3390/nu14091801
A Nutritional Approach for the Management of Chemotherapy-Induced Diarrhea in Patients with Colorectal Cancer
Abstract
This study aimed to determine if dietary modifications using a nutritional regimen could prevent or reduce the incidence of cancer therapy-induced diarrhea in patients with metastatic colorectal cancer and to evaluate the relationship of Vitamin D blood levels with diarrhea severity. Patients with metastatic colorectal cancer were enrolled. A Mediterranean diet, containing some special limitations aiming to reduce the risk of diarrhea, was administered before and during the entire chemotherapy program. Enrolled patients numbering 60/137 (44%) had diarrhea during chemotherapy. Adherence to the diet was high in 36 (26.3%) patients, medium in 94 (68.6%), and low in 7 (5.1%). Mean adherence to the diet was significantly lower in patients who experienced diarrhea with maximum grade 2−3 compared to those who had no diarrhea or grade 1 diarrhea (score = 5.4 ± 1.9 vs. 7.1 ± 1.5, p < 0.001). Patients with higher adherence to the diet had a lower risk of grade 2−3 diarrhea (odds ratio: 0.5 (95% CI: 0.3−0.7, p < 0.001)). In addition, patients who completed a higher number of chemotherapy cycles had an increased risk of grade 2−3 diarrhea (odds ratio: 1.2 (95% CI: 1.0−1.5, p = 0.02)). Of note, a lower level of Vitamin D correlated with an increased risk of G2-G3 diarrhea (p = 0.03). A diet based on vegetables with a controlled fiber content, Mediterranean Modified Healthy Diet (MMHD), is useful to control the incidence of cancer therapy-induced diarrhea.
Keywords: Vitamin D; cancer therapy-induced diarrhea; colorectal cancer; diet.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Effect of Diversion Ileostomy on the Occurrence and Consequences of Chemotherapy-Induced Diarrhea.Dis Colon Rectum. 2016 Mar;59(3):194-200. doi: 10.1097/DCR.0000000000000531. Dis Colon Rectum. 2016. PMID: 26855393
-
A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study.Cancer Chemother Pharmacol. 2018 Jun;81(6):1035-1041. doi: 10.1007/s00280-018-3568-x. Epub 2018 Apr 11. Cancer Chemother Pharmacol. 2018. PMID: 29644459 Clinical Trial.
-
A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan.Support Care Cancer. 2015 Mar;23(3):661-70. doi: 10.1007/s00520-014-2402-1. Epub 2014 Aug 27. Support Care Cancer. 2015. PMID: 25160493 Clinical Trial.
-
[Short-term effects of chemotherapy combined with hydroxycamptothecine and oxaliplatin in treatment of recurrent and metastatic colorectal cancer].Ai Zheng. 2006 Aug;25(8):1035-8. Ai Zheng. 2006. PMID: 16965689 Chinese.
-
Estimating the cost of illness in colorectal cancer patients who were hospitalized for severe chemotherapy-induced diarrhea.Can J Gastroenterol. 2005 Feb;19(2):83-7. doi: 10.1155/2005/618504. Can J Gastroenterol. 2005. PMID: 15729427
Cited by
-
Mediterranean Diet as a Supportive Intervention in Cancer Patients: Current Evidence and Future Directions.Curr Oncol. 2022 Oct 11;29(10):7579-7582. doi: 10.3390/curroncol29100597. Curr Oncol. 2022. PMID: 36290874 Free PMC article.
-
Association between ideal cardiovascular health and bowel conditions among US adults.Front Nutr. 2024 Nov 7;11:1473531. doi: 10.3389/fnut.2024.1473531. eCollection 2024. Front Nutr. 2024. PMID: 39574525 Free PMC article.
-
Functional decline in older breast cancer survivors treated with and without chemotherapy and non-cancer controls: results from the Hurria Older PatiEnts (HOPE) prospective study.J Cancer Surviv. 2024 Aug;18(4):1131-1143. doi: 10.1007/s11764-024-01594-3. Epub 2024 Apr 28. J Cancer Surviv. 2024. PMID: 38678525 Free PMC article.
-
Relationship between dietary fiber intake and chronic diarrhea in adults.World J Clin Cases. 2024 Jul 6;12(19):3692-3700. doi: 10.12998/wjcc.v12.i19.3692. World J Clin Cases. 2024. PMID: 38994290 Free PMC article.
-
Evaluating the role of dietary interventions in reducing chemotherapy toxicities in cancer patients: a systematic review.J Cancer Surviv. 2025 Mar 22. doi: 10.1007/s11764-025-01777-6. Online ahead of print. J Cancer Surviv. 2025. PMID: 40119985 Review.
References
-
- Miroddi M., Sterrantino C., Simonelli I., Ciminata G., Phillips R.S., Calapai G. Risk of grade 3-4 diarrhea and mucositis in colorectal cancer patients receiving anti-EGFR monoclonal antibodies regimens: A meta-analysis of 18 randomized controlled clinical trials. Crit. Rev. Oncol. Hematol. 2015;96:355–371. doi: 10.1016/j.critrevonc.2015.06.004. - DOI - PubMed
-
- Douillard J.Y., Cunningham D., Roth A.D., Navarro M., James R.D., Karasek P., Jandik P., Iveson T., Carmichael J., Alakl M., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet. 2000;355:1041–1047. doi: 10.1016/S0140-6736(00)02034-1. - DOI - PubMed
-
- Saltz L.B., Cox J.V., Blanke C., Rosen L.S., Fehrenbacher L., Moore M.J., Maroun J.A., Ackland S.P., Locker P.K., Pirotta N., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. 2000;343:905–914. doi: 10.1056/NEJM200009283431302. - DOI - PubMed
-
- Tournigand C., André T., Achille E., Lledo G., Flesh M., Mery-Mignard D., Quinaux E., Couteau C., Buyse M., Ganem G., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J. Clin. Oncol. 2004;22:229–237. doi: 10.1200/JCO.2004.05.113. - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical